Did you know? There are different kinds of changes, called mutations, that can happen in the MET gene. These changes can help cancer grow and spread. One type is called c-MET overexpression. This means the cancer cells make too much of a protein called c-MET. 

On May 14, 2025, the U.S. Food and Drug Administration (FDA) announced accelerated approval of Emrelis (telisotuzumab vedotin-tllv) for people with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) who have high c-MET protein over-expression and have previously received systemic therapy.  

This latest approval is based on results from the LUMINOSITY study, which looked at how safe and effective Emrelis (telisotuzumab vedotin-tllv) is for people with non-squamous NSCLC with high c-MET protein over-expression, who do not have an EGFR mutation, and have already received systemic therapy. The study showed a favorable response rate and that responses lasted a meaningful amount of time. This is encouraging news for a population with limited treatment options. 

Emrelis (telisotuzumab vedotin-tllv) is a type of treatment known as an antibody-drug conjugate (ADC). ADCs work by binding directly to a target on the cancer cells, delivering a powerful drug that causes them to die. 

Please speak with your healthcare team for more information about Emrelis (telisotuzumab vedotin-tllv) and see if it may be a good option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436.  

Read the  full FDA announcement.